Answers are grounded in this paper and cite their sources.
Purpose The role of hypofractionated radiotherapy (HFRT) in advanced breast cancer beyond symptom palliation remains underexplored. This study evaluated the efficacy, safety, and prognostic factors of local HFRT combined with systemic therapy, with exploratory tissue-based genomic profiling. Methods This retrospective cohort included 67 advanced breast cancer patients who received HFRT (≥ 5 Gy/fraction, ≤ 10 fractions) to metastatic lesions between 2021 and 2026. Objective response rate (ORR), progression-free survival (PFS), time to next systemic therapy (TTNT), overall survival (OS), and adverse events (AEs) were assessed. Subgroup analyses were performed, and tumor sequencing was performed in 19 patients for somatic mutation analysis. Results The local ORR was 62.7%, with median local PFS of 8.0 months, overall PFS of 6.2 months, TTNT of 6.6 months, and OS of 19.1 months. Local response was independently associated with improved PFS (HR 0.31, 95%CI 0.16–0.59, P < 0.001) and OS (HR 0.29, 95%CI 0.15–0.58, P = 0.001). Liver metastasis was associated with lower response and worse survival. Deeper tumor shrinkage (≥ 50%) among responders was not significantly associated with additional survival benefits. AEs were manageable, with no grade 4–5 events. Common somatic mutations included TP53 (63.2%), PIK3CA (42.1%), and PTEN (36.8%), with no significant associations identified between individual gene mutations and ORR. Conclusion Local HFRT combined with systemic therapy showed favorable efficacy and safety in advanced breast cancer, with local response identified as a strong factor associated with survival benefit. However, no significant association was observed between deeper tumor shrinkage and additional survival benefits.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: